Ferring Pharmaceuticals Polandsp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2004-02-24
Share capital
425,000.00 PLN
Registered address
Szamocka 8, 01-748 Warszawa, Poland
Electronic delivery address
AE:PL-67632-97207-HHVWW-23

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 62 days early. All were audited by a statutory auditor.

  • 202529/04/2026
  • 202429/05/2025
  • 202315/05/2024
  • 202223/06/2023
  • 202119/05/2022
  • 202028/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 51.29mMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 727.74kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 49.89mMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 18.74mMedianUSD 608.93kAverageUSD 11.85m

Authorized Representatives

Felix Von Leonhardi – Management Board Member
Renata Kołodziejczuk – Attorney-in-fact (joint)
Małgorzata Sawko – Attorney-in-fact (joint)
Morten Vaupel – President of the Management Board

Manner of representation

Two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy are authorised to represent the company.

Ownership

OwnerSharesShare valueStake
Ferring B.v.
425$114,802.81100%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2012-01-12.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$37,713
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$79,561
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$31,133

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Olympus Polskasp. z o.o.
ITPS.A.
Orkla CareS.A.
Synkmedsp. z o.o.
Intimexsp. z o.o. + limited partnership
Ivoclar-Vivadent Polskasp. z o.o.
Medif sp. z o.o.sp. k.
PromedS.A.
Billmedsp. z o.o.
Medmess Kropaczewskisp. k.

Change history

DateEvent
2018-11-26PKD change
2015-08-18PKD change
2014-04-15Address change
2012-02-02Address change
2012-02-02Share capital increase

FAQ

Last updated: 2026-10-07